Combined treatment of Taraxaci Herba and R7050 alleviates the symptoms of herpes simplex virus-induced Behçet's disease in rats by 이배환 et al.
Integrative Medicine Research 10 (2021) 100720 
Contents lists available at ScienceDirect 
Integrative Medicine Research 
journal homepage: www.elsevier.com/locate/imr 
Original Article 
Combined treatment of Taraxaci Herba and R7050 alleviates the 
symptoms of herpes simplex virus-induced Behçet’s disease in rats 
Myeounghoon Cha a , Minjee Kwon b , Misun Park a , Jin-Hwan Oh c , Kang-Keyng Sung c , ∗, 
Bae Hwan Lee a , d , ∗
a Department of Physiology, Yonsei University College of Medicine, Seoul, Republic of Korea 
b Department of Nursing, Kyungil University, Gyeongsan, Republic of Korea 
c Jangheung Integrative Medical Hospital, Wonkwang University, Jangheung, Republic of Korea 
d Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea 
a r t i c l e i n f o 
Article history: 
Received 21 September 2020 
Revised 12 January 2021 
Accepted 31 January 2021 





Herpes simplex virus 
SCORAD index 
a b s t r a c t 
Background: Behçet’s disease (BD) is a chronic inflammatory systemic disease that affects multiple or- 
gans. The causes of BD are still unknown, but it is primarily characterized by autoimmune reaction in 
the blood vessels. Current research focuses on treatments that can reduce the non-typical inflammatory 
responses of BD. Nevertheless, studies on improving the inflammatory effect of BD using inflammation 
mechanisms are still insufficient. Therefore, we conducted the integrated treatments related to inflamma- 
tion modulation and achieved alleviation of symptoms in BD mice. 
Methods: To understand the complex etiology of BD and compare its management, the herpes simplex 
virus (HSV)-induced BD mouse model was used. In order to alleviate the inflammatory response in BD 
mice, Taraxaci Herba (TH, herbal medicine), R7050-a TNF α inhibitor, and a mixture of TH and R7050 were 
injected for 2 weeks repetitively. The SCORAD index was examined to evaluate the cutaneous inflamma- 
tions. In addition, histological changes and inflammatory factors were analyzed. 
Results: Repetitive injection of TH and/or R7050 reduced the symptoms of BD and significantly decreased 
IL-6, IL-1 β , and TNF α in blood sera. Moreover, this treatment reduced the ulcers and the deterioration of 
skin. 
Conclusions: The results of our study showed that the down-regulation of inflammatory factors is related 
to the control of immune responses in BD models, suggesting that a mixed drug treatment may be more 
effective in improving the condition of BD. 
© 2021 Published by Elsevier B.V. on behalf of Korea Institute of Oriental Medicine. 
This is an open access article under the CC BY-NC-ND license 






















Behçet’s disease (BD) is a rare multigenetic disorder of un- 
nown etiology. It is a multisystem inflammatory vasculitis char- 
cterized by recurrent oral and genital ulcerations, ocular lesions, 
nd arthritis [1] . Although almost all organs might eventually be 
nvolved, the involvement of the central nervous system and eyes 
an worsen the prognosis; therefore, proper treatment is required ∗ Co-corresponding authors at: Jangheung Integrative Medical Hospital, 
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 http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 2] . A recent study indicated that several factors, including en- 
ironmental pollution, infections, genetically determined pheno- 
ypes, and immune dysregulation, are related to the pathogenesis 
f BD [3] . 
The current treatment of BD is mainly based on the control of 
nflammation by using immunomodulatory or immunosuppressive 
gents. tumor necrosis factor alpha (TNF α), which is one of the 
ulti-functional cytokines, promotes inflammatory response and 
ediates cell death by binding to TNF receptor 1, which triggers 
he extrinsic pathway of apoptosis [ 4 , 5 ]. Since the plasma level
f TNF α is elevated in patients with inflammatory disease, TNF α
as generated interest in the treatment of BD. However, anti-TNF α
herapies are associated with challenges such as their availability, 
otential antigenicity, and tissue distribution [6] . icine. This is an open access article under the CC BY-NC-ND license 

















































































































In traditional medicine, a comprehensive approach with herbal 
edicine has been used for the treatment of inflammatory dis- 
ases including allergy, asthma, multiple sclerosis, coeliac dis- 
ase, glomerulonephritis, hepatitis, and inflammatory bowel dis- 
ase [ 7 , 8 ]. Among them, Taraxaci herba (TH) is widely used as a
raditional medicine for febrifuge and reducing edema [9] . TH is 
erived from the dried herba of Taraxacum mongolicum, and con- 
ists of taraxasterol, choline, inulin, and pectin [10] . It has been 
eported that TH can reduce heat and swelling and also remove 
oxic substances at the site of inflammation [ 11 , 12 ] Another promi-
ent class of biologicals are the anti-TNF drugs that are applied in 
everal inflammatory diseases characterized by dysregulated TNF 
evels. Among them, recent studies on R-7050 found that R7050 
hows excellent effects as a TNF α antagonist. R-7050 was ob- 
erved to be effective as an adjuvant therapy in the treatment of 
erve damage as a TNF receptor complex inhibitor that improves 
he course after intracranial hemorrhage [ 13 , 14 ]. However, studies 
bout the efficacy of TH and R7050 in improving the inflammatory 
ffect in BD are still inadequate. 
In patients with BD, inflammatory activation leads to rheuma- 
oid disease, neurological deterioration, and mucosal skin symp- 
oms, although the exact mechanism is unknown [15] . There are 
ignificant evidence-based data about the management of rheuma- 
oid arthritis, ocular diseases, and mucocutaneous diseases in the 
nimal models of BD. However, there is insufficient evidence re- 
arding the treatment strategies for neurologic and vascular mani- 
estations. Although therapies for reducing inflammation have been 
roposed, the quality of evidence is not high [16] . Emerging pre- 
linical and clinical evidence on BD suggests a potential role of the 
nti-inflammatory response by the innate immune system to con- 
rol the symptoms of BD; however, this idea remains largely unex- 
lored. 
The role of viral infections, such as herpes simplex virus (HSV) 
nfection, in the pathogenesis of Behçet’s disease (BD) has been 
nvestigated for many years. The clinical similarities between her- 
etiform ulcers in BD and ulcers due to HSV infection suggest an 
tiologic role of HSV in BD, and several studies have attempted 
o isolate HSV from the oral ulcers of patients with BD [ 2 , 3 , 17 ].
he species-specificity and inherent abnormality of human leuko- 
yte antigen (HLA) molecules in mice model are also similar to the 
resence of genetic predisposition in BD patients [17] . 
The present study aimed to determine whether the direct use of 
NF α inhibitor (R7050, a selective antagonist of TNF α/TNFR1 path- 
ay), and TH could relieve symptoms of BD, and whether the lev- 
ls of a related cytokine could be reduced by injecting the drug to 
urther modulate the symptoms. The presence or absence of der- 
atitis in BD was scored using the SCORAD index, which includes 
rythema, edema/papulation, oozing/crusting, excoriation, licheni- 
cation, and dryness [ 18 , 19 ]. We also compared the results of in-
egrated treatment using two drugs simultaneously. 
. Methods 
.1. Animals and induction of BD 
All animal experiments were approved by the Institutional An- 
mal Care and Use Committee of Yonsei University Health System 
protocol number 2019–0093), and were performed in accordance 
ith the guidelines for the ethical use of conscious animals in pain 
esearch published by the International Association for the Study 
f Pain. We used 4-week-old male ICR mice ( n = 40, consisting of 
ve groups of eight mice, Orient Bio, Seongnam, Gyeonggi-do, Ko- 
ea) for this study. In each group, four mice per group were used 
or tissue staining, and the others were used for WB. Using the 
ethod described by Sohn et al. [20] , we scratched the earlobes of 
he mice with a needle, and inoculated them with herpes simplex 2 irus-2 (HSV-2) (KBPV-VR-84, Korea Bank for Pathogenic viruses, 
eoul, Korea). Virus inoculation was performed four times within 
 weeks, which was followed by 4 weeks of observation. No HSV- 
noculated mice were included in the control group. All mice were 
red in temperature and light-controlled conventional BL3 rooms 
20–22 °C; 12 h light cycle starting at 8:00 AM), and had free ac- 
ess to food and water. During the experimental period, the ani- 
als were closely observed and photographed. 
.2. Gross observation of BD symptoms 
To classify the symptomatic mice as having BD, we used a pre- 
ious classification [20] . Oral, genital, and other skin ulcers (includ- 
ng oozing and crusting ulcers) as well as ocular symptoms were 
lassified as major indications. The presence of at least two major 
ndications in a mouse were classified as BD. Symptomatic mice 
ere photographed with a digital camera. 
.3. Drug (TNF receptor-1 inhibitor and Taraxaci herba) 
dministration 
The TNF Type-I receptor inhibitor, R7050 (Merck KGaA, Darm- 
tadt, Germany), was dissolved in saline. The selected concentra- 
ion of R7050 was referenced from previous studies [ 14 , 21 ]. In
ddition, anti-inflammatory herbal medicine, Taraxaci Herba (TH 
 kg, SQ-17,069–1–1, Green Pharm. Gyeonggi-do, Korea), was pre- 
ared, as described below. TH was boiled in distilled water (DW) 
p to three times the weight of the herb for 3 h and filtered us-
ng gauze. The filtered TH soup was lyophilized with a freeze dryer 
FreeZone 6 plus Labconco, Kansas City, MO, US) [22] . Finally, 5 to 
% of TH was obtained in powder form. Saline, R-7050 (10 mg/kg), 
nd TH (6 mg/kg) were administered repetitively via the intraperi- 
oneal route for 2 weeks (four times). In addition, mice in the 
H + R -7050 group were injected with each drug at 10-minute in- 
ervals. There was no HSV-inoculated healthy mouse in the control 
roup. 
.4. Histology 
After the mice were sacrificed, tissues were retrieved for post- 
xation in 4% paraformaldehyde in 0.1 M phosphate buffer (4 °C), 
nd then prepared in 30% sucrose in phosphate buffered saline 
ver 24 h. Sagittal sections (12 μm) of the tissues were obtained 
sing a cryostat (Microm HM525; Thermo Scientific, Waltham, MA, 
SA). Sections obtained at similar planes were used for haema- 
oxylin and eosin staining. Tissue sections were washed in DW, fol- 
owed by staining with haematoxylin to stain the nuclei and eosin 
o counterstain the cytoplasmic regions. Stained sections were 
xamined using a microscope (Olympus BX40; Olympus, Tokyo, 
apan). Then, eight tissue samples were randomly selected for each 
roup, and the number of hair follicle cells in the 4X enlarged tis- 
ue pictures was counted and averaged. 
.5. Western blot analysis 
Four weeks later, the mice were anesthetized with an in- 
raperitoneal injection of a mixture of alfaxalone hydrochloride 
40 mg/kg) and xylazine (10 mg/kg). To analyze the inflammatory 
actors in blood, samples were collected from the superior vena 
ava. One microliter of blood per mouse was collected and stored 
t −80 °C in polypropylene tubes until the western blot analysis. 
he microtubes were centrifuged for 5 min at 10,0 0 0 × g , and 
era were collected. Samples were denatured in lithium dodecyl 
ulfate (LDS) buffer containing DTT, and loaded onto a NuPAGE R ©
–12% Bis-Tris Mini gel to perform electrophoresis. Proteins were 
hen transferred to polyvinylidene difluoridine (PVDF) membranes 
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Fig. 1. Comparison of herpes simplex virus (HSV)-induced Behçet’s disease (BD) symptoms in mice. In saline groups with BD symptoms, oral, skin, and genital skin ulcers 
and eye-related changes were observed. However, in the groups injected with TH or R7050 alone, BD symptoms were alleviated, and better outcomes were observed in the 


































































0.45 μm, Merck KGaA, Darmstadt, Germany). The membranes 
ere blocked with 5% BSA in TBST, and incubated overnight at 4 °C 
ith a rabbit polyclonal primary antibody (IL-1 β; abcam ab9722, 
L-6; abcam 208,113, TNF α; abcam 66,579, Cambridge, UK). Next, 
he membranes were washed and incubated with an anti-rabbit 
gG HRP-conjugated secondary antibody for 1 h at room tempera- 
ure. Immuno-reactive proteins were revealed by enhanced chemi- 
uminescence. The band recognized by the primary antibody was 
isualized by using LAS-40 0 0 (Fuji Film Co, Ltd., Tokyo, Japan), and 
ensitometry was measured with Multi Gauge software (Fuji Film 
o, Ltd., Tokyo, Japan). To allow quantification across several gels, 
ne sample was used as an internal calibrator, which was loaded 
n each gel and set to 100%. 
.6. Statistical analysis 
Values are expressed as mean ± SEM, and were compared using 
ne-way analysis of variance (ANOVA) followed by Dunnett’s post 
oc pairwise comparisons (Prism 8, GraphPad Software, San Diego, 
A, US). A p value less than 0.05 was considered statistically sig- 
ificant. 
. Results 
A multisystemic disorder with erythema, edema/papulation, 
ozing/crusting, excoriation, lichenification, and dryness appeared 
n HSV-inoculated mice. Mice with at least two major symptoms 
ere classified as having BD-like symptoms [23] . 
.1. Evaluation of multisystemic disorder in BD mice 
To determine whether anti-inflammatory responses play a role 
n the development of HSV-induced BD symptoms, ICR mice 
ere treated with a mixed solution of saline, TH, R7050, and 
H + R7050 to suppress the inappropriate inflammatory responses. 
ymptoms developed in the inoculated mice, and these included 
ozing/crusting in the facial region, erythema on the scratched ear- 
obe, ocular symptoms (e.g., hypopyon, iridoretinitis, and uveitis), 3 s well as skin edema, lichenification, and papules on the ear- 
obes, genitalia, and other regions, as reported [24] . ( Fig. 1 ) For
nalysis, the SCORAD index (scoring for atopic dermatitis) method 
sed in previous clinical studies [19] was applied for indexing the 
nflammatory symptoms of the skin. In the results as shown in 
ig. 2 , the scores in each group were summed up, and the contri- 
ution of each score was calculated. The index indicated erythema, 
dema/papulation, oozing/crusting, excoriation, lichenification, and 
ryness. It was observed that the symptoms were alleviated, and 
 highly significant difference was also shown between the saline 
roup and the TH-, R7050-, and TH + R7050-injected mice (Control: 
 (0,0,0,0,0,0); Saline: 13.7 (2.2 ± 0.13, 2.1 ± 0.15, 3, 1.9 ± 0.11, 3, 
.5 ± 0.12); TH: 6.5 (1 ± 0.08, 1.5 ± 0.5, 0, 1.5 ± 0.2, 2.5 ± 0.31, 
); R7050: 5.2 (1.5 ± 0.2, 0, 1.5 ± 0.23, 1.2 ± 0.2, 1 ± 0.13, 0); 
H + R7050: 3.5 (0, 1.5 ± 0.14, 2 ± 0.25, 0, 0, 0)). Following the 
njections of TH, R7050, and TH + R7050, skin ulcers gradually de- 
reased and symptoms of alopecia improved in the TH and R7050 
roups (Supplementay Fig. S1). The TH + R7050 group, which was 
njected with the two drugs simultaneously, also showed an im- 
rovement in lesions and inflammation. 
.2. Administration of anti-inflammatory drugs alleviates BD 
ymptoms 
We tried to describe the layers of skin tissue that appear in 
ormal tissues and the morphological characteristics of individual 
ayer. The tissue specimens show the stratum corneum and stra- 
um lucidum, as well as the basement membrane and epidermal 
idge, which make up the epithelial tissue ( Fig. 3 ). Differences in 
kin lesions in mice with BD are presented in Fig. 3 . Histopatho- 
ogical features of erythema, oozing, and crusting in BD are mainly 
haracterized by changes due to the denaturation of the granu- 
ar and stratum corneum. The results comparing the skin tissues 
n each group are shown in Fig. 3 . In control rats, the appear-
nce of normal skin tissue and the presence of hair follicles can be 
onfirmed, and the distinction between the epidermis and dermis 
f the skin can be clearly distinguished. However, damaged skin 
issues due to BD were observed in the saline group. Hair folli- 
les from the dermis were blurred, and the structures of the epi- 
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ermis and dermis were not clearly distinguished. In the TH and 
7050 groups, hair follicles reappeared; however, it was difficult 
o observe changes in the structure of the dermis. In the skin tis- 
ue changes in the TH + R7050 group, the presence of distinct hair 
ollicle cells was identified, and the dermal tissue layer was con- 
rmed. An analysis was attempted by comparing the number of 
air follicle cells in the tissues. Then, as shown in Fig. 4 , eight
issue samples were randomly selected for each group, and the 
umber of hair follicle cells in the 4X enlarged tissue pictures was 
ounted and averaged (Control 43.25 ± 8.66; Saline 12.62 ± 2.82; 
H 28.25 ± 1.48; R7050 29.5 ± 3.25; TH + R7050 34.62 ± 6.89). 
ollowing the symptoms of BD, the number of hair follicles was 
ignificantly reduced in the saline-treated group compared to the 
ontrol group. In addition, the number of hair follicles increased 
n the TH and R7050 groups compared to the saline group. In the 
roup in which TH and R7050 were administered together, a statis- 
ically significant increase in hair follicles was observed compared 
o that in the saline group; however, the difference was not signif- 
cantly different from that of the groups that received TH or R7050 lone. p
4 .3. Down-regulated proinflammatory cytokines by drug 
dministration in BD mice 
To determine the levels of cytokines, sera were analyzed by 
estern blot at 4 weeks after drug administration. The IL-1 β level 
n the saline-injected group was significantly higher than that in 
he control and other groups (Control 1 ± 0.20; Saline 2.32 ± 0.40; 
H 1.34 ± 0.30; R7050 1.33 ± 0.23; TH + R7050 1.05 ± 0.12). The 
evel of IL-6 also increased significantly in the saline-injected group 
ompared to other groups (Control 1 ± 0.13; Saline 2.18 ± 0.28; TH 
.15 ± 0.10; R7050 1.20 ± 0.07; TH + R7050 1.03 ± 0.15). In addition, 
he TNF α level in the saline injected group was also higher com- 
ared to other groups (Control 1 ± 0.27; Saline 2.33 ± 0.26; TH 
.16 ± 0.18; R7050 1.18 ± 0.20; TH + R7050 1.15 ± 0.32). The TH, 
7050, and TH + R7050 groups showed significantly lower levels of 
roinflammatory cytokines compared to the saline-injected group. 
he BD model showed an overall increase in cytokines, but a sig- 
ificant decrease after injection of the drugs. Taken together, these 
esults indicate that TH, R7050, and TH + R7050 may down-regulate 
roinflammatory cytokines in BD mice ( Fig. 5 ). 
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Fig. 3. Structural changes in the epidermis and dermis in the control group. A. Tissue observation after H&E staining with 4X microscope (scale bar: 1 mm). The two squares 
are enlarged and shown in B (upper) and C (bottom). B. Structure of the epidermis. Hair follicle cells could be easily observed in the epidermis of the skin (scale bar: 
500 μm). C. Dermis and subcutaneous tissue of the skin. The composition of normal tissue can be observed (scale bar: 200 μm). Comparison of structural changes in the 
epidermis and dermis in each experimental group (Bottom 3 lines figures). Changes in the skin tissue in each group were observed and compared under the microscope 
(magnifications: 4 ×, 10 ×, and 20 ×). In the saline group, the structure of hair follicles appears to fade; however, in the TH, R7050, and TH + R7050 injection groups, clearer 
and increased number of hair follicles were observed. 
Fig. 4. Comparison of hair follicle cells between the experimental groups. The hair 
follicles were counted. Compared to the control group, the number of hair folli- 
cles was significantly higher in the BD model group injected with saline. In the 
experimental group administered TH, R7050, or TH + R7050 for 4 weeks, the num- 
ber of hair follicles increased. Data are presented as means ± standard error of the 
mean (SEM). ∗∗p < 0.01 vs. Control, # p < 0.05 vs. Saline, as determined by one-way 



























5 . Discussion 
In our study, inflammatory responses induced by HSV and 
hanges in skin tissue were observed in BD mice. By suppress- 
ng the abnormal inflammatory reactions caused by TNF α, an ef- 
ective improvement in BD symptoms was observed. The effect of 
raditional medical treatment methods in reducing inflammation 
as observed using the SCORAD index method [19] . Administering 
nti-inflammatory drugs improved BD symptoms, such as genital 
nd skin ulcers, and decreased the severity score. The changes in 
roinflammatory cytokines, which decreased after the drug admin- 
stration, indicate that the symptoms of BD can be significantly al- 
eviated by regulating the inflammatory responses. 
Recent studies have suggested that proinflammatory cytokines 
ight play a dominant role in triggering chronic autoimmune in- 
ammation, and are considered essential for colitis and promotion 
f various inflammatory symptoms of the skin [ 25 , 26 ]. However, 
lthough biological treatment with anti-inflammatory agents has 
een shown to be effective in BD, research on the mechanisms of 
hese beneficial responses being elucidated[ 27 , 28 ].. Among the cy- 
okines being studied in BD, inhibition of the IL-1 family is the 
rst area of interest. The IL-1 family contains 11 groups of cy- 
okines that regulate many intracellular signaling pathways. IL-1 α
nd IL-1 β are type I receptors, and core receptor-accessory pro- 
eins are the most studied [27] . IL-1 β is a major pre-inflammatory 
ytokine, and is known to up-regulate the innate immunity in re- 
ponse to expression of many chemokines and secondary media- 
ors of inflammation, and to infectious agents [29] . IL-1 β in BD is 
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Fig. 5. Expression of inflammatory factors between the experimental groups. In comparing the changes of IL-1 β , Il-6, and TNF α, a significant increase was observed in 
the BD groups injected with saline. However, the levels of IL-1 β , Il-6, and TNF α were significantly decreased in the in the groups injected with TH or R7050 alone, and 
the TH + R7050-injected group. ∗∗p < 0.01 vs. Control, # p < 0.05 vs. Saline, as determined by one-way ANOVA followed by Dunnett’s post hoc multiple comparison test to 




















































































onsidered to be mainly involved in BD due to the increased lev- 
ls of IL-1 β in the serum of BD patients and the fact that it sup-
resses IL-1 β , leading to stable clinical remission [29] . TH is de- 
ived from the dried whole plant and consists of the taraxasterol, 
holine, inulin, and pectin. Its known effects include reduction of 
eat and swelling, as well as clearance of toxic materials at sites 
f inflammation. R-7050 is a cell-permeable TNF- α receptor antag- 
nist that blocks TNF- α-induced binding of TNF- αRI with TNF αR- 
ssociated death domain protein and receptor interacting protein 
, blocking internalization of the TNF α-TNF αR complex. Previous 
tudies have also indicated that these two drugs can pass eas- 
ly through the BBB [ 14 , 30 ]. In our results, the TH + R7050 group
howed a lower level of IL-1 β compared to the group treated with 
H or R7050 alone. These results suggest that independent appli- 
ation of TH and R7050 can reduce IL-1 β expression and inflam- 
ation; however, their combined use did not show significant ef- 
ects. Among the available IL-1 blockers, the IL-1 receptor antago- 
ists such as Anakira, canakinumab, and gevokizumab, which tar- 
et the IL-1 molecule directly, have been used in BD patients; and 
hey have shown successful IL-1 inhibitory effects, leading to an 
ncreased interest in anti-IL-1 agents for managing BD [31-34] . 
IL-6 consists of multiple cytokines secreted by various cell 
ypes, including T and B lymphocytes, macrophages, osteoblasts, 
broblasts, keratinocytes, and endothelial cells. It is involved in 
any immune pathways and plays a pivotal role in the regula- 
ion of various immune responses, aggravation of acute inflamma- 
ion, and progression to relapse or chronic inflammatory responses 
 35 , 36 ]. Increased plasma IL-6 levels have been reported predomi- 
antly in BD patients, suggesting a correlation with disease activ- 
ty in patients with predominantly neurological involvement [37] . 
ue to the effects of IL-6 on the immune system and inflamma- 
ory processes, IL-6 antagonism is considered a potential therapeu- 
ic strategy in various autoinflammatory and autoimmune disor- 
ers [38] [39] . In the present study, we focused on the changes in
roinflammatory cytokine levels in BD using TH and R7050. The 
ecrease in levels of IL-1 β and IL-6 after TH and/or R7050 in- 
ections showed the immunomodulatory effects of TH and R7050, 
ndicating that they might be effective for the alleviation of BD 
ymptoms. 
In particular, the inhibition of TNF α was reported to be suc- 
essful in controlling inflammation in many patients [40] . The im- 
roved understanding of the mechanisms of TNF α pathway in BD 
as recently opened up new potential opportunities in terms of 6 reatment. TNF α modulation therapy has been revolutionized by 
dvances in the knowledge about the pathogenetic mechanisms 
f BD, namely, the dysfunction and over-secretion of a network 
f proinflammatory molecules, principally TNF- α [28] . Recently, 
nti-TNF α treatments, including infliximab and adalimumab, have 
een reported to be efficient in all severe and refractory BD man- 
festations [41] . Moreover, combination therapy of infliximab and 
ethotrexate was administrated in Japan, and it showed short and 
ong-term efficacy and tolerability, as assessed by abdominal com- 
uted tomography (CT) and colonoscopy. [ 42 , 43 ] Although many 
atients may benefit from treatment with anti-TNF drugs, a ma- 
or challenge is the high number of patients who do not respond 
o therapy. Initial treatment responses have been reported to fail 
n 13 to 40% of patients, and it is difficult to observe the treat- 
ent effect in 50% of patients [44] . In this study, we used an
nti-TNF agent and TH, which is a natural extract. Interestingly, in 
he group that received a mixture of TH and R7050, a decrease 
n the SCORAD score and recovery of skin tissue were observed 
n haematoxylin staining, with a marked improvement in the in- 
ammatory cytokine changes. The hair follicle is a tunnel-shaped 
tructure in the epidermis (outer layer) of the skin. Hair starts 
rowing at the bottom of a hair follicle. The root of the hair con- 
ists of protein cells, and is nourished by the blood from nearby 
lood vessels. Skin abnormalities caused by inflammation induce 
edness and itchiness, and in severe cases, erythema, lichenifi- 
ation and hair loss. Our results showed the reduced inflamma- 
ory response-related follicle changes in the epidermal layer after 
reatment. These results suggest that the combination of a clini- 
ally used proinflammatory inhibitor and naturally-derived TH, as a 
reatment for BD, might be more effective in improving the symp- 
oms of inflammation in BD. However, only a few animals were 
nalyzed in this study, making it difficult to draw firm and defi- 
ite conclusions. Therefore, further large controlled studies involv- 
ng integrated treatment and longer follow-up periods are needed 
o corroborate these observations, and to confirm the efficacy and 
afety of these treatments, which provide a valuable knowledge for 
he treatment of BD. 
In this study, using the HSV-induced BD model, we found that 
educing the inflammatory response is a major factor in alleviating 
he symptoms of BD. In the current study, the potential of integra- 
ive medicine was expected by using effective anti-inflammatory 
rugs together. As a result, the reduction of inflammatory lesions 
f the skin could be detected by the regeneration of the hair folli- 






























































le, however the cytokine analysis did not show a significant syn- 
rgic effect. Nevertheless, our experiment showed that it was not 
ignificant but effective in the recovery of skin edema and ulcers 
nd changes in the inflammatory factors in BD animal model. Al- 
hough, TH + R7050 could not show the significantly improve the 
nflammation-related molecular changes, our results indicated that 
he combination treatment of TH and R7050 could alleviates the 
ymptoms of herpes simplex virus-induced Behçet’s disease. 
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